-
Mashup Score: 0Head-to-head comparison of four COVID-19 vaccines on platelet activation, coagulation and inflammation. The TREASURE study - 1 year(s) ago
Studies exploring alterations in blood coagulation and platelet activation induced by COVID-19 vaccines are not concordant. We aimed to assess the impact of four COVID-19 vaccines on platelet activation, coagulation, and inflammation considering also the immunization dose and the history of SARS-CoV-2 infection.
Source: Thrombosis ResearchCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 0Anticoagulant drug choice in patients who have had bariatric surgery – Presently, DOACs are not the preferred choice - 2 year(s) ago
More than 200,000 bariatric surgeries are performed annually in the United States alone, with a steady increase over the last few years [1]. Anticoagulation is not uncommonly required in these patients: approximately 3% are on chronic anticoagulation pre-operatively for various indications [2], others develop indications immediately postoperatively, and still others require anticoagulation months…
Source: Thrombosis ResearchCategories: Hem/Oncs, Latest HeadlinesTweet-
https://t.co/vqJmo1FKMq
-
-
Mashup Score: 1Incidence and mortality due to thromboembolic events during the COVID-19 pandemic: Multi-sourced population-based health records cohort study - 2 year(s) ago
The COVID-19 pandemic has resulted in an increase in the incidence of hospitalised TE. There were more deaths from TE in the community highlighting a number of mechanisms including the hypercoagulable state associated with COVID-19 infection and potential impact of delays in seeking help.
Source: Thrombosis ResearchCategories: Cardiologists, Latest HeadlinesTweet-
RT @SulemanAktaa: Rates of #TE including #PE & associated mortality during #COVID https://t.co/e4TrIhfBG2 @mmamas1973 @cpgale3 @Dr_R_Nad…
-
-
Mashup Score: 0The effect of Bruton's tyrosine kinase inhibitor ibrutinib on atherothrombus formation under stenotic flow conditions - 2 year(s) ago
Bruton’s kinase (Btk) is critical for collagen-triggered platelet signal transduction. The Btk inhibitor ibrutinib has been shown to selectively block platelet adhesion to atherosclerotic plaque material under laminar arterial flow. However, this has not been studied under a shear gradient, which is characteristic for atherothrombosis.
Source: Thrombosis ResearchCategories: Hem/Oncs, Latest HeadlinesTweet-
Ibrutinib ⬇️ in vitro platelet deposition, thrombus size & contraction on human atherosclerotic plaque around a stenosis when compared to patients not receiving ibrutinib. Interesting but causes HT in vivo so may offset a beneficial effect on CV events https://t.co/4ZknVmX7UW
-
-
Mashup Score: 5
Continuous intravenous unfractionated heparin (UFH) is a mainstay of therapeutic anticoagulation in the acute setting. The two most common laboratory tests for monitoring UFH are the activated partial thromboplastin time (aPTT) and antifactor Xa (anti-Xa) heparin assay. We reviewed the available evidence to evaluate if the choice of monitoring test for UFH therapy is associated with a difference…
Source: Thrombosis ResearchCategories: Hematologists1, Latest HeadlinesTweet-
RT @bbikdeli: No sig difference between #aPTT & #anti-Xa for treatment w UFH. @ThrombosisRese1 https://t.co/yBqGMXBG1y Editorialists @NTC…
-
-
Mashup Score: 2Pulmonary infarction in acute pulmonary embolism - 3 year(s) ago
Pulmonary infarction results from occlusion of the distal pulmonary arteries leading to ischemia, hemorrhage and ultimately necrosis of the lung parenchyma. It is most commonly caused by acute pulmonary embolism (PE), with a reported incidence of around 30%. Following an occlusion of the pulmonary artery, the bronchial arteries are recruited as primary source of perfusion of the pulmonary…
Source: Thrombosis ResearchCategories: Latest Headlines, PediatricsTweet-
Pulmonary infarction in acute pulmonary embolism - Thrombosis Research https://t.co/hCoEhIsxye
-
-
Mashup Score: 8Management of high-risk pulmonary embolism in pregnancy - 3 year(s) ago
Pregnancy-associated high-risk pulmonary embolism (PE) is among the most frequent causes of maternal mortality in the Western world, by causing hemodynamic instability and circulatory failure through a large thrombotic pulmonary obstruction. The very challenging management of these dramatic situations comprises the need to quickly select a therapy of pulmonary reperfusion or hemodynamic…
Source: Thrombosis ResearchCategories: Cardiologists, Latest HeadlinesTweet-
RT @CardioOb: Management of high-risk pulmonary embolism in pregnancy #CardioObstetrics https://t.co/bFU5WOVHFZ https://t.co/ubQ2N5s6K1
-
-
Mashup Score: 10Management of high-risk pulmonary embolism in pregnancy - 3 year(s) ago
Pregnancy-associated high-risk pulmonary embolism (PE) is among the most frequent causes of maternal mortality in the Western world, by causing hemodynamic instability and circulatory failure through a large thrombotic pulmonary obstruction. The very challenging management of these dramatic situations comprises the need to quickly select a therapy of pulmonary reperfusion or hemodynamic…
Source: Thrombosis ResearchCategories: Cardiologists, Latest HeadlinesTweet-
Management of high-risk pulmonary embolism in pregnancy 📌High-risk pregnancy-associated PE is a cause of maternal mortality. 📌Systemic thrombolysis is suggested as the first-line treatment. https://t.co/ucOLeE88Aa #CardioObstetrics @ThrombosisRese1 https://t.co/Lw9O3VRKlH
-
-
Mashup Score: 4
Long-term dual antiplatelet therapy (DAPT) has substantially reduced the risk of post-percutaneous coronary intervention (PCI) myocardial infarction and stent thrombosis at the expense of major bleeding. We hypothesized that a short-term DAPT followed by extended P2Y12 inhibitor monotherapy might be appropriate for patients with both high ischemic and bleeding risks.
Source: Thrombosis ResearchCategories: Cardiologists, Latest HeadlinesTweet-
#P2Y12i monotherapy and #DAPT after percutaneous coronary intervention: An updated #metaanalysis https://t.co/v6T25abNdZ
-
-
Mashup Score: 2
The AMPLIFY trial found significantly lower major bleeding (MB) and similar recurrent venous thromboembolism (VTE) risks associated with apixaban vs warfarin among patients with VTE.
Source: Thrombosis ResearchCategories: Cardiologists, Latest HeadlinesTweet-
Safety and effectiveness of #DOAC compared with warfarin among clinically-relevant subgroups of #VTE US population. https://t.co/oxAV1DN9FP
-
'Four COVID-19 vaccines administered to a large population sample induce a transient inflammatory response, with no onset of platelet activation' https://t.co/KZVaHA538O